Mergers & Acquisitions ·
On September 3, 2026, Apogee Therapeutics completed its merger with Andor LLC, a subsidiary of AbbVie Inc., becoming…
APGEApogee Therapeutics, Inc.
On September 3, 2026, Apogee Therapeutics completed its merger with Andor LLC, a subsidiary of AbbVie Inc., becoming an indirect wholly owned subsidiary. Shareholders received $135.11 per share in cash, excluding those holding appraisal rights or affiliated entities. The transaction carries a total equity value of approximately $10.9 billion and was funded by AbbVie using cash on hand and debt. Concurrently, all directors and executive officers resigned from the board and management positions. Apogee Therapeutics Common Stock was suspended from trading on Nasdaq effective September 4, 2026, with plans to file Form 15 to terminate registration under Section 12(g) of the Securities Exchange Act. The company operates in the biotechnology industry, focusing on developing novel therapies for inflammatory and immune-mediated diseases.